Literature DB >> 30536313

Clinicopathologic and prognostic relevance of miR-1256 in colorectal cancer: a preliminary clinical study.

Z-Y Liu1, L Yang, H-Y Chang.   

Abstract

OBJECTIVE: MicroRNAs (miRNAs) as a new class of biomarkers have been explored in recent studies. We investigate whether miR-1256 could be considered as powerful biomarkers for predicting the prognosis of colorectal cancer (CRC). PATIENTS AND METHODS: The expression of miR-1256 in CRC was compared with matched normal tissue and using qRT-PCR. The correlation of miR-1256 expression with clinicopathological factors was statistically analyzed. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Univariate and multivariate Cox regression analysis was used to identify the independent risk factors for CRC.
RESULTS: We found that miR-1256 level in CRC tissues is notably reduced compared to matched non-cancerous specimens (p < 0.01), and the expression of miR-1256 was significantly correlated with TNM stage (p = 0.000) and lymph node metastasis (p < 0.07). Kaplan-Meier analysis showed that CRC patients with low miR-1256 expression level had distinctly shorter overall survival (p = 0.004) and disease-free survival (p < 0.001) than patients with high miR-1256 expression level. Finally, Cox regression analyses showed that low miR-1256 expression might be an independent prognostic parameter to predict poor prognosis of CRC patients.
CONCLUSIONS: We firstly provided evidence that low miR-1256 expression was associated with the progression of CRC and could be used as a prognostic biomarker for breast cancer. Further studies are needed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536313     DOI: 10.26355/eurrev_201811_16391

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  MiR-1256 inhibits cell proliferation and cell cycle progression in papillary thyroid cancer by targeting 5-hydroxy tryptamine receptor 3A.

Authors:  Chaowen Wu; Liyuan Ma; Hongfa Wei; Furong Nie; Jie Ning; Tao Jiang
Journal:  Hum Cell       Date:  2020-03-04       Impact factor: 4.174

2.  A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.

Authors:  James Saller; Kun Jiang; Yin Xiong; Sean J Yoder; Kevin Neill; Jose M Pimiento; Luis Pena; F Scott Corbett; Anthony Magliocco; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2021-03-13       Impact factor: 3.199

3.  Eight Differential miRNAs in DN Identified by Microarray Analysis as Novel Biomarkers.

Authors:  Chao Tu; Lan Wei; Liangzhi Wang; Ying Tang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-24       Impact factor: 3.168

4.  circHECTD1 facilitates glutaminolysis to promote gastric cancer progression by targeting miR-1256 and activating β-catenin/c-Myc signaling.

Authors:  Juan Cai; Zhiqiang Chen; Jinguo Wang; Junfeng Wang; Xianjun Chen; Linhu Liang; Min Huang; Zhengrong Zhang; Xueliang Zuo
Journal:  Cell Death Dis       Date:  2019-08-02       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.